These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 19589755)

  • 1. APhA2009 House of Delegates: serving the association and the profession.
    Weitzel KW; Tisdale JE; Mattingly J
    J Am Pharm Assoc (2003); 2009; 49(4):474-80. PubMed ID: 19589755
    [No Abstract]   [Full Text] [Related]  

  • 2. Report of the 2009 APhA House of Delegates: actions of the legislative body of the American Pharmacists Association.
    J Am Pharm Assoc (2003); 2009; 49(4):492-4. PubMed ID: 19589759
    [No Abstract]   [Full Text] [Related]  

  • 3. Grassroots lobbying: an important tool for pharmacy. Developing grassroots advocate.
    Boyle C
    J Am Pharm Assoc (2003); 2004; 44(1):5-6. PubMed ID: 14965144
    [No Abstract]   [Full Text] [Related]  

  • 4. Report of the 2010 APhA House of Delegates: actions of the legislative body of the American Pharmacists Association.
    J Am Pharm Assoc (2003); 2010; 50(4):471-2. PubMed ID: 20621862
    [No Abstract]   [Full Text] [Related]  

  • 5. A defense of the learned intermediary doctrine.
    Goetz RB; Growdon KR
    Food Drug Law J; 2008; 63(2):421-38. PubMed ID: 18561470
    [No Abstract]   [Full Text] [Related]  

  • 6. APhA2010 House of Delegates: paving the way for the profession's best practices.
    Thomas RA; Voytilla R; Knutson AR
    J Am Pharm Assoc (2003); 2010; 50(4):450-8. PubMed ID: 20621859
    [No Abstract]   [Full Text] [Related]  

  • 7. Report of the APhA and APhA-ASP Houses of Delegates.
    Bzowyckyj A; Oestreich J; Kirk LM
    J Am Pharm Assoc (2003); 2015; 55(4):340, 342-4, 346-7. PubMed ID: 26161477
    [No Abstract]   [Full Text] [Related]  

  • 8. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 9. Professionalism in pharmacy. Professionalism and the APhA House of Delegates.
    Prince VT
    J Am Pharm Assoc (2003); 2003; 43(4):452-4. PubMed ID: 12952308
    [No Abstract]   [Full Text] [Related]  

  • 10. Report of the 2013 APhA House of Delegates.
    J Am Pharm Assoc (2003); 2013; 53(4):365-7. PubMed ID: 23892807
    [No Abstract]   [Full Text] [Related]  

  • 11. Grassroots lobbying: an important tool for pharmacy. Lobbying can lead to acknowledgment as health care providers.
    Lipowski E
    J Am Pharm Assoc (2003); 2004; 44(1):6-7. PubMed ID: 15008167
    [No Abstract]   [Full Text] [Related]  

  • 12. Report of the 2015 APhA House of Delegates.
    J Am Pharm Assoc (2003); 2015; 55(4):364-75. PubMed ID: 26161480
    [No Abstract]   [Full Text] [Related]  

  • 13. Professional policies approved by the 2010 ASHP House of Delegates.
    Am J Health Syst Pharm; 2010 Aug; 67(16):e50-4. PubMed ID: 20689110
    [No Abstract]   [Full Text] [Related]  

  • 14. Prescribing opportunities for pharmacists in rural areas.
    Ahmad A; Khan MU
    Res Social Adm Pharm; 2016; 12(5):811-2. PubMed ID: 27157865
    [No Abstract]   [Full Text] [Related]  

  • 15. American Pharmaceutical Association House of Delegates, May 13-18, 1978, Montreal, Quebec, Canada. Report of the Policy Committee on Organizational Affairs.
    Am Pharm; 1978 Jul; 18(8 Spec No):32-5. PubMed ID: 665505
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacy's stars climb to reach our potential.
    Hamilton L
    J Am Pharm Assoc (2003); 2009; 49(4):482-5. PubMed ID: 19589756
    [No Abstract]   [Full Text] [Related]  

  • 17. APhA2007 House of Delegates: improving practice today, preparing for and protecting the profession's future.
    Weitzel K; Farley JF; Anderson JJ; Whisman TR
    J Am Pharm Assoc (2003); 2007; 47(5):548, 550-2, 559-60, passim. PubMed ID: 17848339
    [No Abstract]   [Full Text] [Related]  

  • 18. Prescription for fairness: a new approach to tort liability of brand-name and generic drug manufacturers.
    Rostron A
    Duke Law J; 2011 Feb; 60(5):1123-91. PubMed ID: 21365961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The new Food and Drug Administration drug package insert: implications for patient safety and clinical care.
    Watson KT; Barash PG
    Anesth Analg; 2009 Jan; 108(1):211-8. PubMed ID: 19095852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A professional association as network and communicating node: the Pharmaceutical Society of Australasia, 1857-1918.
    Boyce G
    Aust Econ Hist Rev; 1999; 39(3):258-83. PubMed ID: 19391275
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.